Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
30 participants
OBSERVATIONAL
2023-05-29
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* to find specific histologic features in different tissues to help the differential diagnosis from other histiocytoses
* to describe the value of chitotriosidase activity to screen this condition
* to describe the value of various tissue biopsies in confirming the diagnosis
* to describe the nature of polyvinylpyrrolidone accumulation in tissue macrophages by novel special microscopic techniques
* to find new tandem mass spectrometry methodology to prove polyvinylpyrrolidone accumulation in macrophages
* to show that polyvinylpyrrolidone treatment activates macrophages to histiocytes and causes povidone accumulation within the cells in in vitro experiments
* to evaluate the pathology of macrophage activation to histiocytes by transcriptomics
The patient history will be collected from the data produced by follow-up of cases followed up in a single center. A subgroup of participants will be given an opportunity to sign informed consent to give access to/donate blood and tissue samples to search for techniques to prove polyvinylpyrrolidone storage within histiocytes, and to search for transcriptomics signal(s) in histiocytes.
Researchers will compare blood and tissue samples from the biobank as controls.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Systemic Histiocytosis
NCT07157683
Histiocytosis and Inflammatory Manifestations in Patients with H Syndrome
NCT06742073
Optical Coherence Tomography Imaging in Systemic Sclerosis
NCT04532151
Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
NCT03816189
Subtypes and Prognostic Factors in Erdheim-Chester Disease
NCT06317246
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition, if a study participant who is followed up clinically, signs informed consent, monocytes are separated from a blood sample, differentiated to macrophages, and exposed to polyvinylpyrrolidone. Various novel methods will be utilized to explore polyvinylpyrrolidone within histiocytes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Injecting drug induced histiocytosis
No intervention
Chitotriosidase
The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
Mass spectrometry
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
scanning electron microscope with energy-dispersive X-ray spectroscopy
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
Fluorescence microscopy
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
Transcriptomics
To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chitotriosidase
The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
Mass spectrometry
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
scanning electron microscope with energy-dispersive X-ray spectroscopy
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
Fluorescence microscopy
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
Transcriptomics
To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampere University
OTHER
University of Oulu
OTHER
University of Turku
OTHER
University of Helsinki
OTHER
Tampere University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pasi I Nevalainen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Senior consultant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tampere University Hospital
Tampere, Pirkanmaa, Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R20105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.